Latest Ratios: P/E Ratio 22.0x · EV/EBITDA 10.7x · ROE 18.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12.1B | $10.8B | $9.4B | $6.8B | $6.0B | $5.2B | $6.6B | $5.5B | $4.9B | $3.9B | $3.3B |
| Enterprise Value | $14.7B | $13.5B | $12.1B | $9.6B | $9.0B | $8.6B | $9.9B | $8.7B | $7.3B | $6.4B | $6.2B |
| P/E Ratio → | 22.02 | 19.16 | 20.71 | 19.23 | 22.15 | 12.63 | 23.07 | 15.26 | 16.74 | 14.61 | 12.66 |
| P/S Ratio | 2.04 | 1.83 | 1.76 | 1.41 | 1.38 | 1.30 | 1.84 | 1.19 | 1.14 | 1.00 | 0.90 |
| P/B Ratio | 3.81 | 3.31 | 3.31 | 2.94 | 3.23 | 2.17 | 3.28 | 2.83 | 2.62 | 2.37 | 3.06 |
| P/FCF | 27.56 | 24.70 | 26.20 | 25.25 | 49.34 | 31.59 | 22.13 | 23.68 | 9.95 | 9.47 | 8.10 |
| P/OCF | 10.30 | 9.23 | 9.41 | 7.94 | 8.51 | 7.26 | 9.31 | 8.62 | 6.42 | 5.94 | 5.39 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.27 | 2.25 | 2.00 | 2.06 | 2.15 | 2.77 | 1.90 | 1.72 | 1.64 | 1.71 |
| EV / EBITDA | 10.65 | 9.75 | 10.37 | 4.80 | 10.27 | 9.82 | 13.36 | 9.58 | 8.33 | 7.71 | 7.59 |
| EV / EBIT | 13.97 | 12.51 | 13.60 | 13.10 | 14.33 | 12.90 | 18.41 | 12.09 | 11.46 | 9.87 | 9.54 |
| EV / FCF | — | 30.64 | 33.49 | 35.81 | 73.75 | 52.44 | 33.33 | 37.75 | 14.92 | 15.59 | 15.50 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.7% | 95.7% | 41.6% | 41.3% | 40.3% | 42.4% | 95.2% | 96.4% | 96.3% | 96.2% | 96.2% |
| Operating Margin | 17.7% | 17.7% | 16.1% | 35.9% | 14.5% | 16.4% | — | 15.0% | 15.9% | 16.6% | 17.8% |
| Net Profit Margin | 9.5% | 9.5% | 8.5% | 7.3% | 6.2% | 10.3% | 8.0% | 7.8% | 6.8% | 6.9% | 6.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.5% | 18.5% | 17.7% | 16.9% | 12.7% | 18.7% | 14.4% | 18.9% | 16.6% | 20.0% | 25.2% |
| ROA | 8.3% | 8.3% | 7.2% | 6.0% | 4.3% | 6.2% | 4.5% | 6.3% | 5.8% | 5.7% | 5.3% |
| ROIC | 13.9% | 13.9% | 12.2% | 26.0% | 8.9% | 8.9% | — | 10.9% | 12.0% | 11.9% | 12.1% |
| ROCE | 17.6% | 17.6% | 15.5% | 32.8% | 11.3% | 11.1% | — | 14.0% | 15.3% | 15.1% | 15.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.83 | 0.95 | 1.28 | 1.61 | 1.45 | 1.77 | 1.73 | 1.34 | 1.57 | 2.83 |
| Debt / EBITDA | 1.97 | 1.97 | 2.33 | 1.47 | 3.42 | 3.96 | 4.79 | 3.67 | 2.85 | 3.09 | 3.67 |
| Net Debt / Equity | — | 0.80 | 0.92 | 1.23 | 1.60 | 1.43 | 1.66 | 1.68 | 1.31 | 1.53 | 2.79 |
| Net Debt / EBITDA | 1.89 | 1.89 | 2.26 | 1.42 | 3.40 | 3.90 | 4.49 | 3.57 | 2.77 | 3.03 | 3.62 |
| Debt / FCF | — | 5.94 | 7.30 | 10.57 | 24.41 | 20.85 | 11.19 | 14.07 | 4.97 | 6.12 | 7.39 |
| Interest Coverage | 8.74 | 8.74 | 6.46 | 5.10 | 3.57 | 4.07 | 2.92 | 4.52 | 4.35 | 4.22 | 3.80 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.08 | 1.08 | 1.05 | 1.28 | 1.25 | 1.23 | 1.32 | 1.05 | 0.98 | 1.36 | 1.38 |
| Quick Ratio | 1.08 | 1.08 | 1.05 | 1.28 | 1.25 | 1.23 | 1.32 | 1.05 | 0.90 | 1.24 | 1.25 |
| Cash Ratio | 0.17 | 0.17 | 0.10 | 0.22 | 0.04 | 0.07 | 0.31 | 0.13 | 0.10 | 0.11 | 0.09 |
| Asset Turnover | — | 0.84 | 0.82 | 0.79 | 0.77 | 0.58 | 0.55 | 0.76 | 0.82 | 0.80 | 0.78 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 2.69 | 2.39 | 2.30 |
| Days Sales Outstanding | — | 38.08 | 40.68 | 46.50 | 45.06 | 45.65 | 57.62 | 39.53 | 39.91 | 44.03 | 44.47 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.6% | 0.7% | 0.7% | 0.9% | 1.6% | 2.2% | 1.7% | 2.0% | 2.1% | 2.3% | 2.6% |
| Payout Ratio | 12.6% | 12.6% | 13.8% | 17.2% | 36.5% | 27.2% | 39.4% | 30.3% | 34.5% | 33.8% | 33.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.5% | 5.2% | 4.8% | 5.2% | 4.5% | 7.9% | 4.3% | 6.6% | 6.0% | 6.8% | 7.9% |
| FCF Yield | 3.6% | 4.0% | 3.8% | 4.0% | 2.0% | 3.2% | 4.5% | 4.2% | 10.0% | 10.6% | 12.3% |
| Buyback Yield | 1.3% | 1.5% | 0.3% | 0.1% | 0.1% | 0.3% | 0.1% | 0.8% | 1.3% | 1.0% | 2.0% |
| Total Shareholder Yield | 1.9% | 2.1% | 1.0% | 1.0% | 1.8% | 2.4% | 1.8% | 2.8% | 3.4% | 3.3% | 4.6% |
| Shares Outstanding | — | $102M | $102M | $101M | $100M | $100M | $100M | $99M | $100M | $99M | $100M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EHC stock.
Encompass Health Corporation's current P/E ratio is 22.0x. The historical average is 19.1x. This places it at the 78th percentile of its historical range.
Encompass Health Corporation's current EV/EBITDA is 10.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.8x.
Encompass Health Corporation's return on equity (ROE) is 18.5%. The historical average is 23.7%.
Based on historical data, Encompass Health Corporation is trading at a P/E of 22.0x. This is at the 78th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Encompass Health Corporation's current dividend yield is 0.57% with a payout ratio of 12.6%.
Encompass Health Corporation has 95.7% gross margin and 17.7% operating margin. Operating margin between 10-20% is typical for established companies.
Encompass Health Corporation's Debt/EBITDA ratio is 2.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Government payer concentration risk
Metrics are mathematically derived from official filings.
Margin Expansion Despite Labor Pressures
Operating margin expanded from 15.5% in Q3 2024 to 19.0% in Q1 2026, while net margin improved to 12.3%, reflecting operating leverage and cost discipline. According to recent financial statements, gross margin volatility (41-48%) suggests labor cost variability.
The reported gross margin swings between 41% and 48% likely reflect the classification of clinical labor as an operating expense rather than cost of goods sold, a common convention in healthcare services. The steady expansion in operating margin from 15.5% to 19.0% over the past two years indicates that revenue growth is outpacing fixed cost growth, a sign of operating leverage. However, the Q2 2026 net margin of 9.6% dipped from Q1's 12.3%, possibly due to one-time items or tax rate fluctuations, warranting monitoring for sustainability.
Stable Returns on Invested Capital
ROIC has remained in a narrow 3.0-3.8% band over the past ten quarters, with ROE ranging from 4.0% to 5.9%. As reported in financial statements, these returns are modest but stable, reflecting a capital-intensive model with heavy PPE investment.
The stability of ROIC around 3.5% suggests that EHC is generating consistent returns on its growing asset base, but the absolute level is low compared to the cost of capital, implying that value creation is modest. The improvement in ROE from 4.1% in Q3 2024 to 5.9% in Q1 2026 is driven by margin expansion and a declining equity base due to buybacks, but the trend is not yet a clear compounding story. Investors should monitor whether de novo hospital investments can lift ROIC above the current plateau.
Working Capital Efficiency Stable
Asset turnover has been flat at 0.22x over the past ten quarters, while DSO improved from 43 days in Q1 2024 to 39 days in Q2 2026. Based on reported figures, the cash conversion cycle is minimal, indicating efficient working capital management.
The stable asset turnover of 0.22x reflects the capital-intensive nature of hospital operations, where revenue per dollar of assets is inherently low. The improvement in DSO from 43 to 39 days suggests better receivables collection, likely due to payer mix shifts toward Medicare Advantage. The absence of inventory data and minimal DPO fluctuations indicate that working capital is not a major source of cash flow variability, consistent with the prior finding that working capital changes are less than 1% of revenue.
Deleveraging Trend Improves Coverage
Debt-to-equity improved from 1.21 in Q1 2024 to 0.82 in Q2 2026, while interest coverage rose from 6.07x to 8.98x. According to recent SEC filings, total debt remained stable near $2.8B, indicating deleveraging through equity growth.
The consistent decline in D/E from 1.21 to 0.82 over ten quarters is a positive sign, as it suggests the company is growing equity faster than debt, partly due to retained earnings. Interest coverage improved from 6.07x to 8.98x, providing a comfortable cushion for debt service. However, the reported D/E of 0.82 appears unusually low for a capital-intensive hospital operator, and the prior balance sheet analysis flagged potential off-balance-sheet obligations, so investors should verify the completeness of the debt figures.
Thin Cash Buffer but Improving Liquidity
Current ratio improved from 1.05 in Q1 2024 to 1.19 in Q2 2026, but cash remains low at $107.7M, representing only 1.4% of total assets. As reported in financial statements, this suggests a tight liquidity position relative to the company's scale.
The current ratio above 1.0 indicates that current assets exceed current liabilities, but the thin cash balance of $107.7M against a $7.5B asset base leaves little room for unexpected cash needs. The improvement in the current ratio from 1.05 to 1.19 is driven by higher receivables and other current assets, not cash accumulation. Under a severe stress scenario, such as a sudden reimbursement cut, the company would likely rely on its revolving credit facility, given the minimal cash buffer.
Misapplied Debt-to-Equity Ratio
The reported D/E of 0.82 is likely understated for a capital-intensive hospital operator, as it may exclude operating lease liabilities and other off-balance-sheet obligations. Based on reported figures, this ratio obscures true leverage and should be adjusted for leases.
The D/E ratio is commonly used to assess leverage, but for EHC, the reported figure of 0.82 appears inconsistent with the sector norm and the company's heavy PPE investment. The prior balance sheet analysis noted that PPE is 60% of total assets, and the company likely has significant operating leases for facilities that are not captured in the reported debt. A more appropriate measure would be to capitalize operating leases and include them in debt, which would likely raise the effective D/E and lower interest coverage. Investors should adjust for lease liabilities to get a true picture of financial risk.